IE 11 is not supported. For an optimal experience visit our site on another browser.

FDA approves first at-home genetic test to assess breast cancer risk


The kit from the company 23andMe tests for three mutations and is available without a prescription — though the test has limitations and it is recommended that the results are confirmed with a doctor.